{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/background-information/causes-risk-factors/","result":{"pageContext":{"chapter":{"id":"8bfc3751-dc6d-58d5-9548-38ebf176bc48","slug":"causes-risk-factors","fullItemName":"Causes and risk factors","depth":2,"htmlHeader":"<!-- begin field ae4677ae-995c-4ec0-97bc-3e185f6ca531 --><h2>What are the causes and risk factors?</h2><!-- end field ae4677ae-995c-4ec0-97bc-3e185f6ca531 -->","summary":"","htmlStringContent":"<!-- begin item 4772346e-4747-40a0-8689-27359a08b204 --><!-- begin field a1cb7812-9963-4caa-8e3f-0ff6b0e61ec8 --><ul><li><strong>Superficial vein thrombosis is most often associated with prothrombotic conditions characterized by one or more of the components of the Virchow triad: vessel wall damage, venous stasis, and hypercoagulability of blood </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">Almeida, 2019</a>]<strong>. </strong><ul><li>Thrombus formation in the vein is likely to be the result of interplay between the damaged blood vessel, the coagulation cascade, the fibrinolytic system, platelet activation, and activation of the inflammatory process. However, the specific relation between these processes is unclear [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2018</a>]. </li></ul></li><li><strong>Varicose veins are the most common risk factors for superficial vein thrombosis of the lower legs</strong><strong> </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">Cosmi, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">Almeida, 2019</a>]<strong>. </strong><ul><li>Their dilatation and tortuosity predispose to stasis, inflammation, and thrombosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">Almeida, 2019</a>].</li><li>About 80% of people with superficial vein thrombosis of the lower limbs have pre-existing varicose veins with or without chronic venous insufficiency [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">Cosmi, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">Thrombosis Canada, 2018</a>]. </li></ul></li><li><strong>Other risk factors include:</strong><ul><li><strong>Thrombophilia </strong>— abnormalities of coagulation are associated with superficial vein thrombosis, especially in the absence of varicose veins and in people with superficial vein thrombosis involving the greater saphenous vein trunk [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2018</a>]. The main coagulation abnormalities associated with superficial vein thrombosis are factor V Leiden mutation (16%), prothrombin 20210 mutation (10%), and deficiencies in antithrombin III, protein C, or protein S (10%) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2015</a>].</li><li><strong>Autoimmune disease</strong> — autoimmune diseases, particularly Behcet's and Buerger's disease, are associated with superficial vein thrombosis. About 53% of people with Behcet's disease will experience an episode of superficial vein thrombosis usually within 5 years of the diagnosis of Behcet's disease (rarely superficial vein thrombosis precedes the diagnosis). Superficial vein thrombosis (more commonly <a class=\"topic-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/background-information/definition/\">migratory thrombophlebitis</a>) is thought to occur in 27–50% of people with Buerger's disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2018</a>]. </li><li><strong>Previous history of superficial vein thrombosis</strong> — this is likey to be an important predictor of future episodes, especially in people with persistent risk factors, such as varicose veins [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2018</a>]. </li><li><strong>Intravenous (IV) injections or cannulation </strong>— superficial vein thrombosis commonly occurs after vessel wall damage caused by IV injection or infusion (especially if an irritant substance was infused), mechanical injuries (for example during cannulation or hemodynamic procedures), or sclerotherapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">Almeida, 2019</a>].</li><li><strong>Cancer</strong> — evidence from small retrospective cohort studies suggests that 10–15% of people with superficial vein thrombosis may have a diagnosis of cancer. <a class=\"topic-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/background-information/definition/\">Migratory thrombophlebitis</a> is often associated with a serious underlying cause, such as cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2018</a>].</li><li><strong>Pregnancy and up to 6 weeks after delivery </strong>— pregnancy-related changes, such as increase in procoagulant factors and reduced fibrinolytic activity, may explain the increased risk during pregnancy, particularly in the puerperium. Venous dilation (and the resulting venous stasis), particularly in the third trimester, is also a risk factor for superficial vein thrombosis during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2018</a>]. </li><li><strong>Female sex</strong> — superficial vein thrombosis is more common in women than men, possibly because of the increased prevalence of varicose veins during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2018</a>]. </li><li><strong>Older age</strong> — the incidence of superficial vein thrombosis increases with age, possibly because the prevalence of varicose veins increases with age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">NICE, 2013</a>]. The incidence of superficial vein thrombosis has been reported as 0.05–0.31 in 100 per year during third decade to 1.8–2.2 in 100 per year in eighth decade [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2018</a>]. </li><li><strong>Prolonged immobilization</strong> — prolonged immobilization (for example due to long-haul flight or hospitalization) may predisposes to venous stasis and/or hypercoagulability of blood [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2018</a>].</li><li><strong>Oral contraceptives or hormone replacement therapy (HRT)</strong> — there is a 2 to 6-fold increased relative risk of venous thrombotic events (often including superficial vein thrombosis) in oral contraceptive users and a 2 to 4-fold increased risk among oral HRT users [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2018</a>]. </li><li><strong>Obesity</strong> — there is a 2.6-fold increased risk of superficial vein thrombosis in people who are overweight compared with people who are not, independent of the presence of varicose veins. Obesity predisposes to venous stasis and is associated with haemostatic changes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/references/\">BMJ, 2018</a>]. </li></ul></li></ul><!-- end field a1cb7812-9963-4caa-8e3f-0ff6b0e61ec8 --><!-- end item 4772346e-4747-40a0-8689-27359a08b204 -->","topic":{"id":"07820562-ab2f-5ea0-9097-3e6e5a62bec4","topicId":"3c0e3637-8623-4aa4-9bdf-83c4ead61135","topicName":"Superficial vein thrombosis (superficial thrombophlebitis)","slug":"superficial-vein-thrombosis-superficial-thrombophlebitis","lastRevised":"Last revised in March 2020","chapters":[{"id":"a5f3a42e-3e23-59d7-83fb-fd26995ebf74","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1ceec510-5b3b-59b2-be08-fde928defc1e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"8b0cc395-7b80-5e19-a891-b27b1d88c9f3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"75c7c081-3b2a-5f62-aead-766ba5534a36","slug":"changes","fullItemName":"Changes"},{"id":"fcc6e0b2-bfab-56d2-a1e0-57e5f3f6c19a","slug":"update","fullItemName":"Update"}]},{"id":"6da7aa90-c506-5e57-baed-74b22c09af0a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8a802f98-487d-5c7e-829e-4a9e669fe875","slug":"goals","fullItemName":"Goals"},{"id":"7dff5216-bc4a-529e-854f-a128cb8b54ca","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"999e411a-0346-5c64-aa2d-eba133633715","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fed9fa0e-2eb0-5385-b244-1efe9fad43ce","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"58585f51-d63a-5cf7-bd5e-f14b6dd9c02a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"62ad8730-5197-5854-acff-ffd86c7f8b92","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5d82d4b3-7ef8-52e7-a668-a65cc11d7bf7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"63f70d2c-b895-556e-8108-242a922f573d","slug":"definition","fullItemName":"Definition"},{"id":"8bfc3751-dc6d-58d5-9548-38ebf176bc48","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"8b1679ef-efa4-5e5e-8690-815334d03623","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b23bb9bc-355d-5db3-909c-ba53a4e4ed95","slug":"complications","fullItemName":"Complications"},{"id":"898b7fad-5295-5eef-991c-921d6b584b9c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a7a8c85c-9ce4-5f12-a1f5-23a4ebba755d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"f7b2717f-67b0-51d3-802e-6289738de5fd","slug":"assessment","fullItemName":"Assessment"},{"id":"c4ead320-38b8-564e-b12e-14547b74132b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"feb9b5f1-73aa-5b36-adca-1c0cf461f9fa","fullItemName":"Management","slug":"management","subChapters":[{"id":"b2e8f26a-d211-5c11-8c71-c772eea8dde7","slug":"management-of-superficial-vein-thrombosis","fullItemName":"Scenario: Management of superficial vein thrombosis"}]},{"id":"ce1a244a-7eef-554a-b0fd-97c7358b1c5a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"98221bb6-71ac-5332-8985-2100a5306385","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3b6f9e44-2ba1-5f2a-a188-d838e155e461","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"21be8a1b-6557-5a82-8b2c-b0e11bd94c6f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"71a14a91-6970-576c-a048-a5e79a477304","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f6bee233-b8a0-577f-874c-2612e21a7dff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fd0ecbc9-ffa5-52d9-839e-435308bda796","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ccd8f8d7-dbcb-5110-ba6c-fe88bca09f07","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5d82d4b3-7ef8-52e7-a668-a65cc11d7bf7","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}